Key result
Exenatide significantly reduced reactive oxygen species generation by 22% and nuclear factor-κB binding by 26% after 12 weeks (P<0.05), independent of weight loss.
Why the study?
Does exenatide reduce inflammatory markers in obese patients with elevated HbA1c?
RCT (n=24)
randomized
Does exenatide reduce inflammatory markers in obese patients with elevated HbA1c?
Exenatide exerts a rapid, weight-independent antiinflammatory effect at the cellular and molecular level, which may contribute to antiatherogenic benefits.
Answers are grounded in this paper and cite their sources.
Exenatide offers weight-independent anti-inflammatory effects in obese patients with elevated HbA1c; extends mechanistic RCT data for potential antiatherogenic actions.
OBJECTIVE: Our objective was to determine whether exenatide exerts an antiinflammatory effect. RESEARCH DESIGN AND METHODS: Twenty-four patients were prospectively randomized to be injected sc with either exenatide 10 μg twice daily [n = 12; mean age = 56 ± 3 yr; mean body mass index = 39.8 ± 2 kg/m(2); mean glycosylated hemoglobin (HbA1c) = 8.6 ± 0.4%] or placebo twice daily (n = 12; mean age = 54 ± 4 yr; mean body mass index = 39.1 ± 1.6 kg/m(2); mean HbA1c = 8.5 ± 0.3%) for 12 wk. Fasting blood samples were obtained at 0, 3, 6, and 12 wk. Blood samples were also collected for up to 6 h after a single dose of exenatide (5 μg) or placebo. RESULTS: Fasting blood glucose fell from 139 ± 17 to 110 ± 9 mg/dl, HbA1c from 8.6 ± 0.4 to 7.4 ± 0.5% (P < 0.05), and free fatty acids by 21 ± 5% from baseline (P < 0.05) with exenatide. There was no weight loss. There was a significant reduction in reactive oxygen species generation and nuclear factor-κB binding by 22 ± 9 and 26 ± 7%, respectively, and the mRNA expression of TNFα, IL-1β, JNK-1, TLR-2, TLR-4, and SOCS-3 in mononuclear cells by 31 ± 12, 22 ± 10, 20 ± 11, 22 ± 9, 16 ± 7, and 31 ± 10%, respectively (P < 0.05 for all) after 12 wk of exenatide. After a single injection of exenatide, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive oxygen species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression, 18 ± 7% in JNK-1 expression, 24 ± 12% in TLR-4 expression, and 23 ± 11% in SOCS-3 expression (P < 0.05 for all). The plasma concentrations of monocyte chemoattractant protein-1, matrix metalloproteinase-9, serum amyloid A, and IL-6 were suppressed after 12 wk exenatide treatment by 15 ± 7, 20 ± 11, 16 ± 7, and 22 ± 12%, respectively (P < 0.05 for all). CONCLUSIONS: Exenatide exerts a rapid antiinflammatory effect at the cellular and molecular level. This may contribute to a potentially beneficial antiatherogenic effect. This effect was independent of weight loss.
No takes yet. Share an insight, caveat, or question.
Chaudhuri et al. (2011) reported an RCT. exenatide vs. placebo was evaluated on reactive oxygen species generation and nuclear factor-κB binding (p=<0.05). Exenatide significantly reduced reactive oxygen species generation by 22% and nuclear factor-κB binding by 26% after 12 weeks (P<0.05), independent of weight loss.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: